Thrombolysis in Cervical Artery Dissection - Data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database
European Journal of Neurology, 05/08/2012Engelter ST et al.
As thrombolysis was neither independently associated with unfavourable outcome nor with an excess of symptomatic bleedings, the findings suggest thrombolysis should not be withheld in cervical artery dissection (CeADStroke) patients. However, the lack of any trend towards a benefit of thrombolysis may indicate the legitimacy to search for more efficient treatment options including mechanical revascularization strategies.
The authors used a multicentre CeADStroke database to compare CeADStroke patients treated with and without thrombolysis.
Main outcome measures were favourable 3-month outcome (modified Rankin Scale 0-2) and ‘major haemorrhage’ [any intracranial haemorrhage (ICH) and major extracranial haemorrhage].
Adjusted odds ratios [OR (95% confidence intervals)] were calculated on the whole database and on propensity-matched groups.
Among 616 CeADStroke patients, 68 (11.0%) received thrombolysis; which was used in 55 (81%) intravenously.
Thrombolyzed patients had more severe strokes (median NIHSS score 16 vs. 3; P < 0.001) and more often occlusion of the dissected artery (66.2% vs. 39.4%; P < 0.001).
After adjustment for stroke severity and vessel occlusion, the likelihood for favourable outcome did not differ between the treatment groups [ORadjusted 0.95 (95% CI 0.45–2.00)].
The propensity matching score model showed that the odds to recover favourably were virtually identical for 64 thrombolyzed and 64 non-thrombolyzed-matched CeADStroke patients [OR 1.00 (0.49-2.00)].
Haemorrhages occurred in 4 (5.9%) thrombolyzed patients, all being asymptomatic ICHs.
In the non-thrombolysis group, 3 (0.6%) patients had major haemorrhages [asymptomatic ICH (n = 2) and major extracranial haemorrhage (n = 1)].
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.